Rossari's Strong Revenue Growth Masked by Sharp Profit Decline
Rossari Biotech posted robust 28% YoY revenue growth in Q1 FY27, but profit fell sharply both sequentially and on a margin basis.
Rossari Biotech's Q1 FY27 results show a clear divergence: revenue climbed to a new high of ₹697 crore, but profit slumped 24% from the previous quarter, squeezing net margins.
Rossari Biotech started FY27 with impressive top-line momentum but faced significant pressure on profitability. Revenue for the quarter ended June 2026 jumped 28.2% year-on-year to ₹697.2 crore, yet profit after tax grew a modest 4.4% to ₹35.09 crore. More strikingly, profit fell 23.7% compared to the strong March 2026 quarter, even as revenue inched up 1.8% sequentially.
The divergence between sales and earnings points to a sharp contraction in net profit margin. At 5.0%, the Q1 FY27 margin is down 120 basis points from the same quarter last year and well below the 5.9% average of the last twelve months (TTM). This suggests rising costs or a less favorable sales mix are offsetting the benefits of higher revenue.
A look at the last five quarters shows revenue has been on a steady upward trajectory, consistently setting new highs. Profitability, however, has been more volatile, with the latest quarter marking a notable step down from the peak margin achieved in Q4 FY26.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 697.2YoY +28% | 684.86 | 543.72 |
| Profit (₹ Cr) | 35.09YoY +4.4% | 45.97 | 33.6 |
| Net Profit Margin (%) | 5.0YoY -19% | 6.7 | 6.2 |
Key Points
- The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.31.
- Return on Equity (RoE) stood at 11.88% for the period.
- The stock trades at a P/E of 14.0, a significant discount to the industry average of 38.9, reflecting investor concerns that have also seen the share price decline nearly 25% over the past year.
The challenge for Rossari in the coming quarters will be to translate its robust sales growth back into stronger bottom-line performance and restore its profit margins.
Live Chart
· ROSSARI
(BSE)
ISIN: INE02A801020
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.